written on 22.04.2014
Tags:
,

Gilead's Sovaldi turns in outsize Q1 sales

TAGS: ,

Powered by sales that averaged more than $25 million a day for brand-new hep C drug Sovaldi, Gilead Sciences beat all expectations, with quarterly sales that nearly doubled and profits that tripled in the first quarter.

Latest Report